Dr. Giovanna Panzeca is a postdoctoral researcher in medicinal chemistry.
She earned her Master's degree in Pharmaceutical Chemistry and Technology (cum laude) from the University of Palermo.
Following her graduation, she held an 18-month research fellowship at the National Research Council (CNR) in Palermo, focusing on the synthesis and characterization of heterocyclic scaffolds with anticancer and antioxidant properties.
Between 2019 and 2022, she pursued a PhD in Molecular and Biomolecular Sciences at the University of Palermo—conferred with the Doctor Europaeus label—specializing in protein kinase inhibitors and the synthesis of nature-inspired analogues. During her doctoral tenure, she spent five months as a visiting researcher at the Cancer Center Amsterdam (Amsterdam UMC), performing biological evaluations on pancreatic ductal adenocarcinoma (PDAC) cell lines.
Since 2023, she has been a postdoctoral researcher at the University of Siena, focusing on the design of novel therapeutic agents for rare and infectious diseases, as well as peptide-based therapeutics for oncology.
Notably, she co-first authored a 2026 review in Medicinal Research Reviews on FLT3 inhibitors for acute myeloid leukemia. Alongside her research, she actively mentors thesis students, has presented her work at national and international conferences, and was awarded the Best Poster Prize at EAMHC 2019.
Dr. Giovanna Panzeca is a postdoctoral researcher in medicinal chemistry.
She earned her Master's degree in Pharmaceutical Chemistry and Technology (cum laude) from the University of Palermo.
Following her graduation, she held an 18-month research fellowship at the National Research Council (CNR) in Palermo, focusing on the synthesis and characterization of heterocyclic scaffolds with anticancer and antioxidant properties.
Between 2019 and 2022, she pursued a PhD in Molecular and Biomolecular Sciences at the University of Palermo—conferred with the Doctor Europaeus label—specializing in protein kinase inhibitors and the synthesis of nature-inspired analogues. During her doctoral tenure, she spent five months as a visiting researcher at the Cancer Center Amsterdam (Amsterdam UMC), performing biological evaluations on pancreatic ductal adenocarcinoma (PDAC) cell lines.
Since 2023, she has been a postdoctoral researcher at the University of Siena, focusing on the design of novel therapeutic agents for rare and infectious diseases, as well as peptide-based therapeutics for oncology.
Notably, she co-first authored a 2026 review in Medicinal Research Reviews on FLT3 inhibitors for acute myeloid leukemia. Alongside her research, she actively mentors thesis students, has presented her work at national and international conferences, and was awarded the Best Poster Prize at EAMHC 2019.